Company / Shareholders' Equity
Seres Therapeutics, Inc. Shareholders' Equity History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$13.8M
FY2025
5-year range
-$48.3M / $174.8M
FY2021-FY2025
Trend
-89.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from -$48M in FY2021 to $205M in FY2017.
Based on SEC 10-K filings.
$14M in FY2025 with a 3-year CAGR of -57.1%.
Declined from $175M to $14M over the past 3 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -57.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -57.1%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 89.5% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.8M | -89.5% |
| FY2023 | $131.5M | -24.7% |
| FY2022 | $174.8M | +461.6% |
| FY2021 | -$48.3M | -0.6% |
| FY2020 | -$48.0M | -179.2% |
| FY2019 | $60.7M | -54.2% |
| FY2018 | $132.6M | -35.4% |
| FY2017 | $205.4M | +868.7% |
| FY2016 | -$26.7M | -140.4% |
| FY2015 | -$11.1M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026